Oncotarget: Bacterial Therapy Experiments in Prostate Cancer
Channel: Oncotarget
Date: 2021-11-03

Oncotarget published this trending research paper on November 3, 2020, entitled, "Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model" by researchers from the Cancer Research Center, Columbia, MO; Department of Immunobiology, Yale University, New Haven, CT; Department of Radiology and Department of Physics and Astronomy, University of Missouri, Columbia, MO; Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO; Department of Psychological Sciences, Institute for Data Science & Informatics, University of Missouri, Columbia, MO; Department of Biology, DeSales University, Center Valley, PA; Division of Biological Sciences, University of Missouri, Columbia, MO.

Abstract:
Conventional cancer chemotherapies are not fully efficacious and do not target tumors, leading to significant treatment-related morbidities. A number of genetically attenuated cancer-targeting bacteria are being developed to safely target tumors in vivo. Here we report the toxicological, tumor-targeting, and efficacy profiles of Salmonella enterica serovar Typhimurium CRC2631 in a syngeneic and autochthonous TRAMP model of aggressive prostate cancer. CRC2631 preferentially colonize primary and metastatic tumors in the TRAMP animals. In addition, longitudinal whole genome sequencing studies of CRC2631 recovered from prostate tumor tissues demonstrate that CRC2631 is genetically stable. Moreover, tumor-targeted CRC2631 generates an anti-tumor immune response. Combination of CRC2631 with checkpoint blockade reduces metastasis burden. Collectively, these findings demonstrate a potential for CRC2631 in cancer immunotherapy strategies.

Press release - https://www.oncotarget.com/news/pr/evaluations-in-the-tramp-prostate-cancer-model/

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27769

DOI - https://doi.org/10.18632/oncotarget.27769

Full text - https://www.oncotarget.com/article/27769/text/

Correspondence to - Yves C. Chabu - chabuc@missouri.edu

Keywords - salmonella, cancer targeting, prostate cancer, immunotherapy, TRAMP

About Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957